Care delivery and site capacity is the operating layer that turns older-patient demand into staffed visits, treatments, procedures, stays, discharges, and home-care starts. The stack includes acute-care hospitals, ambulatory surgery centers, dialysis clinics, behavioral-health facilities, inpatient rehabilitation hospitals, and alternate-site infusion networks. The economics work only when a provider has clinical staff, licensed rooms or beds, payer authorization, and revenue per case or treatment that covers wages, supplies, drugs, denials, bad debt, facility investment, and debt cost. HCA is the source-backed scale anchor; THC and EHC rank ahead of DVA and UHS because outpatient surgery and inpatient rehab are cleaner capacity-conversion routes in this node.
What the stack is: physical care sites and clinical operating networks that deliver hospital, outpatient surgery, dialysis, behavioral-health, rehab, and infusion care.
What it does in the theme chain: converts aging, chronic-disease, procedure, behavioral, and post-acute demand into billable units such as admissions, adjusted admissions, surgical cases, dialysis treatments, patient days, rehab discharges, and infusion revenue.
Main pieces: staffed beds, operating rooms, ambulatory surgery center rooms, dialysis chairs, clinical labor, pharmacy and supply purchasing, payer contracting, authorization workflows, billing systems, receivables collection, and maintenance capex.
Where it sits: in local hospital markets, freestanding surgery centers, outpatient dialysis clinics, behavioral hospitals, inpatient rehab hospitals, and home or alternate-site infusion routes between prescribers, payers, nurses, pharmacies, and patients.
How the parent theme uses it: the parent aging-demand theme needs care sites that can absorb more older and chronic patients without losing margin to labor, reimbursement, authorization, or collection friction.
Terms used later: equivalent admissions adjust hospital admissions for outpatient activity; same-facility cases and patient days show organic utilization; revenue per case, treatment, discharge, or patient day measures price and acuity; authorization means payer approval before care is delivered or paid; conversion means revenue becoming EBITDA, cash flow, or per-share earnings after operating costs and capex.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, setup labels, confirmation triggers, invalidation levels, and chart provenance. Durable company, sector, policy, and theme research stays in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Capacity conversion gateStaffed sites must turn patient demand into paid units and cash.
Hospitals, ASCs, dialysis clinics, behavioral facilities, rehab hospitals, and infusion networks need payer approval, clinical labor, throughput, and clean collections before higher utilization improves equity value.
Positive proofHCA, THC, and EHC show the clearest current capacity routes.
HCA has scale and filed local coverage; THC has USPI outpatient surgery exposure; EHC has rehab bed and discharge conversion.
Conversion gateUnit revenue must cover labor, supply, denial, and capex drag.
Watch admissions, cases, treatments, patient days, discharges, revenue per unit, EBITDA margin, cash flow, and leverage.
Primary constraintAuthorization, reimbursement, staffing, and legal risk can absorb volume.
DVA needs treatment stabilization; UHS and ACHC need behavioral growth without policy or quality issues dominating the read.
Demand sourceAging + chronic care
Care siteHospitals, ASCs, clinics
Collection routePayer authorization + billing
Proof pointEBITDA, FCF, units
Care delivery and site capacity is where aging demand becomes billable volume. Hospitals, ASCs, dialysis clinics, behavioral facilities, rehab beds, and home-infusion networks benefit only when they have staffed sites, payer authorization, and unit economics that turn patient demand into admissions, procedures, treatments, patient days, discharges, or infusion starts. HCA is the broad source-backed anchor, while THC and EHC deserve promoted watch status because outpatient surgery and inpatient rehab are direct conversion points for health-care utilization.
The main tailwind is care shifting toward lower-cost or more specialized sites while older patients need more procedures, chronic-care visits, rehab stays, and behavioral capacity. THC's USPI platform gives the page its clearest outpatient migration angle. EHC gives the cleanest rehab-capacity angle. HCA provides the broad hospital-system read, and UHS plus ACHC capture behavioral demand where admissions and patient days are the key proof points.
The headwinds are labor availability, reimbursement, authorization friction, legal risk, leverage, and weak volume conversion. DVA has strong price action and local coverage, but treatments were slightly down in Q1. SGRY needs better EBITDA and leverage proof. OPCH needs evidence that alternate-site infusion can recover from authorization and drug-access issues. UHS and ACHC need behavioral volume growth without Medicaid, legal, or governance risk becoming the dominant story.
Static setup labels were inherited from the 2026-06-11 node package. Local discovery now has daily_ohlc through 2026-06-12, so stale setup thresholds must be refreshed before use as current trading evidence. Selected-security right-rail charts call the report API with as_of=latest.
Basket
This basket ranks care-site operators by node fit, evidence quality, and current conversion risk. The formal metadata core remains HCA, UHS, and DVA because those names have filed local knowledge lanes. The ranked research basket promotes THC and EHC because official Q1 sources show cleaner site-capacity conversion than several source-backed names, while SGRY, ACHC, and OPCH stay tail/watch rows.
Broad acute-care and ambulatory operator with the deepest local evidence and the largest care-site base.
Market cap$96.5B
Next earningsJul 24, 2026 est.
Latest qtr revenue$19.109B
Role in stack
HCA sells hospital, emergency, surgical, and ambulatory care to commercial, Medicare, Medicaid, Exchange, and self-pay patients. Aging demand becomes revenue through admissions, equivalent admissions, ER visits, surgeries, revenue per equivalent admission, and funded facility capex.
Revenue mix
HCA operated 189 hospitals and about 2,600 ambulatory sites at March 31, 2026. Revenue is dominated by inpatient, outpatient, emergency, surgical, and ancillary care inside local market clusters; Texas and Florida concentration remains a payer-mix and weather-risk caveat in the local lane.
Latest qtr revenue
Q1 2026 revenue was $19.109B. Same-facility admissions rose 0.9%, equivalent admissions rose 1.3%, and revenue per equivalent admission rose 3.1%, while outpatient surgeries fell 1.7%.
THCTenet Healthcare
Outpatient surgery platform where USPI cases and revenue per case test the site-of-care shift.
Market cap$16.4B
Next earningsNot confirmed
Latest qtr revenue$5.368B
Role in stack
Tenet's USPI platform owns and manages ambulatory surgery centers and surgical hospitals. The node mechanism is outpatient procedure migration: physician case flow becomes facility revenue, revenue per case, adjusted EBITDA, and cash after minority-interest distributions.
Revenue mix
Q1 2026 ambulatory net operating revenue was $1.320B, and hospital segment net operating revenue was $4.048B. USPI had interests in 541 ASCs and 26 surgical hospitals; the rank is driven by ambulatory economics even though hospitals remain the larger revenue pool.
Latest qtr revenue
Q1 2026 consolidated net operating revenue was $5.368B, excluding the CommonSpirit contract-termination revenue item. Ambulatory same-facility revenue rose 5.3%, revenue per case rose 5.6%, and surgical cases fell 0.3%.
EHCEncompass Health
Inpatient rehab capacity operator where beds, discharges, and revenue per discharge convert post-acute demand.
Market cap$10.5B
Next earningsNot confirmed
Latest qtr revenue$1.587B
Role in stack
Encompass operates inpatient rehabilitation hospitals for patients recovering from stroke, orthopedic, cardiac, pulmonary, neurological, and other serious conditions. Demand converts through staffed beds, discharge volume, revenue per discharge, therapist availability, and managed-care authorization.
Revenue mix
Inpatient rehabilitation is the primary route. The node exposure is owned and joint-venture rehab hospitals, new hospital openings, added beds in existing hospitals, occupancy, discharge growth, and payer authorization quality.
Latest qtr revenue
Q1 2026 net operating revenue was $1.5866B, up from $1.4554B in Q1 2025. The company also raised 2026 net operating revenue guidance to $6.375B-$6.470B.
Dialysis capacity and cash-flow name where revenue per treatment is stronger than current treatment growth.
Market cap$12.8B
Next earningsAug 2026 est.
Latest qtr revenue$3.416B
Role in stack
DaVita runs outpatient dialysis centers for end-stage renal disease patients. Recurring treatment demand becomes economics through treatment volume, revenue per treatment, clinic cost control, commercial mix, ESRD reimbursement, free cash flow, and buybacks.
Revenue mix
FY2025 U.S. dialysis was 86% of consolidated revenue. Q1 2026 U.S. dialysis revenue was $2.942B; the remainder is international dialysis, integrated kidney care, and other ancillary operations.
Latest qtr revenue
Q1 2026 total revenue was $3.415548B. U.S. dialysis treatments were 7.030M, down 0.2% year over year, while revenue per treatment rose to $417.59.
Acute and behavioral operator where behavioral patient days look steadier than acute admissions.
Market cap$10.3B
Next earningsLate Jul 2026 est.
Latest qtr revenue$4.495B
Role in stack
UHS operates acute-care and behavioral-health facilities. The node mechanism is admissions, adjusted admissions, behavioral patient days, revenue per adjusted admission or patient day, supplemental Medicaid collections, and cash flow after capex.
Revenue mix
Q1 2026 segment revenue was roughly 58% acute care and 42% behavioral health. Behavioral health is the differentiated route, while acute care adds broader hospital volume, payer-mix, and supplemental-payment exposure.
Latest qtr revenue
Q1 2026 net revenue was $4.495B. Behavioral same-facility revenue rose 7.3%, admissions rose 1.2%, and adjusted patient days rose 1.6%; acute adjusted admissions were softer.
SGRYSurgery Partners
Higher-beta short-stay surgery operator with direct ASC exposure and leverage proof still pending.
Market cap$1.9B
Next earningsNot confirmed
Latest qtr revenue$810.9M
Role in stack
Surgery Partners owns and operates short-stay surgical facilities. The node mechanism is physician recruitment, case growth, revenue per case, margin, free cash flow, and deleveraging.
Revenue mix
Revenue is driven by surgical facilities and management services tied to consolidated and nonconsolidated facilities. Same-facility revenue and case volume decide whether the platform is scaling organically.
Latest qtr revenue
Q1 2026 revenue was $810.9M. Same-facility revenue rose 4.4%, same-facility cases rose 0.6%, adjusted EBITDA was $102.3M, and net leverage was about 4.3x.
ACHCAcadia Healthcare
Behavioral-capacity operator where legal, quality, and regulatory risk keep the rank low.
Market cap$2.3B
Next earningsNot confirmed
Latest qtr revenueSource limited
Role in stack
Acadia operates behavioral-health facilities, acute psychiatric capacity, specialty treatment facilities, and residential programs. Behavioral demand converts through admissions, patient days, revenue per patient day, bed additions, payer mix, and facility quality controls.
Revenue mix
The current page has no filed ACHC security lane. The report-side source package treats behavioral facilities and patient-day growth as the relevant route, but legal, regulatory, Medicaid, and governance issues require a discount to the operating read.
Latest qtr revenue
Q1 2026 total revenue was not verified in this worker's accessible official-source pass. Keep ACHC as a source-gap row until the official release or 10-Q amount is rechecked and filed.
OPCHOption Care Health
Alternate-site infusion route that fits the theme but has the weakest current revenue and EBITDA proof.
Market cap$3.2B
Next earningsNot confirmed
Latest qtr revenue$1.351B
Role in stack
Option Care Health provides home and alternate-site infusion services. The theme converts through patient starts, drug availability, nursing capacity, reauthorizations, therapy mix, payer collections, gross profit, and adjusted EBITDA.
Revenue mix
Home and alternate-site infusion services are the primary route. Revenue depends on therapy mix, payer authorization, specialty drug access, patient starts, nursing availability, and collection timing.
Latest qtr revenue
Q1 2026 net revenue was $1.3507B, up 1.3%. Adjusted EBITDA fell 6.3%, and management said revenue growth momentum was weak, so OPCH remains the lowest-ranked watch row.
Market caps use read-only discovery instruments.market_cap queried on 2026-06-13. HCA, DVA, and UHS next-earnings windows come from local security-lane or raw-source calendar fields and are labeled estimated; official IR event pages and Nasdaq pages checked on 2026-06-13 did not confirm the remaining dates. Latest-quarter revenue uses Q1 2026 official company releases or SEC exhibits where accessible; ACHC remained unverified in this worker pass.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesis
Patient demand becomes paid units
What confirms
Admissions, adjusted admissions, ASC cases, dialysis treatments, behavioral patient days, rehab discharges, and infusion starts rise while revenue per unit holds.
What weakens or invalidates
Volume grows but collections, margins, or free cash flow deteriorate because labor, drugs, supplies, denials, bad debt, or capex absorb the revenue.
Watch next
Q2-Q3 volume
Revenue per unit
EBITDA margin
02Site capacity
Staffed space produces throughput
What confirms
Staffed beds, ASC rooms, dialysis chairs, rehab beds, and home-infusion capacity add revenue without a matching rise in contract labor or authorization delays.
What weakens or invalidates
Capacity additions sit idle, surgery cases stay weak, staff shortages persist, or payer authorization friction delays patient starts.
Watch next
HCA outpatient surgery
THC and SGRY cases
EHC bed additions
OPCH reauthorizations
03Unit economics
Price and acuity cover cost
What confirms
Revenue per equivalent admission, case, treatment, discharge, or patient day grows faster than wages, supplies, pharmacy cost, and bad debt.
What weakens or invalidates
Reported revenue is mostly price or acuity while case volume, EBITDA margin, operating cash flow, or free cash flow weakens.
Watch next
HCA margin near 20%
DVA treatment economics
THC ambulatory margin
SGRY leverage
04Customer and payer
Coverage supports collection
What confirms
Medicare, Medicaid, commercial, Medicare Advantage, and supplemental-payment assumptions hold; DSO, denial rate, bad debt, and uncompensated care stay contained.
What weakens or invalidates
Provider-tax limits, Medicaid work requirements, ACA subsidy pressure, Medicare Advantage denials, supplemental-payment cuts, or payer reauthorizations reduce cash conversion.
Watch next
CMS IPPS/PFS updates
UHS supplemental Medicaid
EHC managed-care authorization
HCA payer mix
05Funding and leverage
Cash funds sites and debt
What confirms
Operating cash flow funds capex, debt service, and selective buybacks or M&A without weakening leverage, revolver availability, or credit-market access.
What weakens or invalidates
Debt cost, refinancing spreads, working-capital drag, buybacks, or acquisition funding outrun EBITDA and free cash flow.
Watch next
HCA debt and buybacks
DVA FCF guide
UHS Talkspace financing
SGRY deleveraging
06Policy and quality
Regulation stays manageable
What confirms
Facility operators keep quality metrics stable, investigations do not widen, state licensing remains intact, and legal reserves fall as a share of revenue.
What weakens or invalidates
New investigations, settlements, facility closures, staffing deficiencies, governance disputes, or safety issues impair volume credibility.
Watch next
ACHC disclosures
UHS legal updates
Facility surveys
State licensing actions
07Stale condition
Evidence window remains current
What confirms
Discovery daily_ohlc, official filings, source lanes, and report metadata are refreshed together before the page is used as a current trading read.
What weakens or invalidates
A new trading week, earnings release, guidance cut, reimbursement change, legal update, or debt/equity financing changes the evidence window.
Tenet events page and Nasdaq earnings pages for source-gap names were checked 2026-06-13. No official or credible concrete next-earnings date was confirmed for THC, EHC, SGRY, ACHC, or OPCH in this worker pass.
Encompass Health events page was checked 2026-06-13 and did not display a confirmed next earnings event in the static page text available to this worker.
Discovery And Chart Provenance
Read-only discovery coverage checks used python -m discovery.cli status HCA --json, python -m discovery.cli lineage-status --ticker HCA --dataset daily_ohlc --limit 3 --json, and read-only DuckDB queries against ../discovery/data/discovery.duckdb.
All eight tickers have daily_ohlc through 2026-06-12. HCA, THC, EHC, DVA, UHS, SGRY, and OPCH each have 1,278 daily rows in the local store; ACHC has 1,279.
Market caps came from read-only instruments.market_cap on 2026-06-13: HCA $96.5B, THC $16.4B, EHC $10.5B, DVA $12.8B, UHS $10.3B, SGRY $1.9B, ACHC $2.3B, and OPCH $3.2B.
The right-rail chart contract is /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. Charts should render weekly OHLC from daily_ohlc with first open, weekly high, weekly low, final close, summed volume, a three-year visible horizon, 20-week EMA, and 100-week EMA when enough history exists.
The page uses selected-security right-rail charts rather than embedded static chart packages or full OHLC payloads.
The basket ranking came from 10 primary research subagents and one merge/select subagent. The merge selected HCA, THC, EHC, DVA, UHS, SGRY, ACHC, OPCH as the displayed order while keeping the formal metadata core as HCA, UHS, and DVA.
Basket Source Notes
Latest-quarter revenue periods are Q1 2026 for every displayed ticker. HCA, THC, EHC, DVA, UHS, SGRY, and OPCH use official company releases or SEC exhibits linked above. ACHC revenue was not verified because the official Acadia source could not be retrieved through this worker's web pass.
Next-earnings fields are intentionally conservative. HCA uses the local security lane's July 24, 2026 expected Q2 print; DVA uses the local source's August 2026 expected window; UHS uses the local source's late July 2026 expected window. These are estimates, not official company confirmations.
THC, EHC, SGRY, ACHC, and OPCH cards use Not confirmed for next earnings because official events pages or available calendar pages did not provide a credible concrete date in this worker pass.
Known Gaps
THC, EHC, SGRY, ACHC, and OPCH have fresh local market data and official Q1 source checks, but no filed local security lanes. They should remain source-gap candidates until canonical lanes or equivalent report-side source packages are built.
EHC overlaps the senior/post-acute capacity debate by care category, but this node owns it as an operator because the economics are discharges, staffed beds, and revenue per discharge rather than rent, NOI, cap rates, or tenant coverage.
OPCH is the weakest current proof point in the basket because the alternate-site model fits the theme better than the latest revenue, authorization, and EBITDA evidence.
Static setup labels and thresholds from 2026-06-11 are stale versus local daily_ohlc through 2026-06-12. Refresh setup levels before using the page as current trading evidence.
Local 13F holdings were empty in the prior discovery status package, so this page does not make holder-concentration claims.